

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Maria Cristina Piroso,^{1,2*} Marianna Sassone,^{3*} Barbara Kiesewetter,^{4*} Armando Lopez Guillermo,⁵ Liliana Devizzi,⁶ Eva Domingo Domènech,⁷ Alessandra Tucci,⁸ Donato Mannina,⁹ Michele Merli,¹⁰ Antonio Salar,¹¹ Carlo Visco,¹² Fabiana Esposito,¹ Luisella Bonomini,² Emanuele Zucca,^{1,2,13#} Andrés J. M. Ferreri^{3#} and Markus Raderer^{4#}

¹Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; ²Institute of Oncology Research, Bellinzona, Switzerland; ³Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy; ⁴Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria; ⁵Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain; ⁶Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy; ⁷Department of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona, Spain; ⁸Division of Hematology, AO Spedali Civili di Brescia, Brescia, Italy; ⁹Hematology Unit, AO Papardo, Messina, Italy, ¹⁰Department of Hematology Ospedale di Circolo di Varese, Varese, Italy; ¹¹Department of Clinical Hematology Hospital del Mar, Barcelona, Spain; ¹²Department of Medicine, Section of Hematology, University of Verona, Verona, Italy and ¹³Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland.

**MCP, MS and BK contributed equally as co-first authors.*

#EZ, AJMF and MR contributed equally as co-senior authors.

Correspondence:

M.C. PIROSA - maria.pirosa@eoc.ch

<https://doi.org/10.3324/haematol.2022.281963>

Supplementary data

Table S1: Response by anatomic site of disease

| Anatomic Site | CR <i>N</i> | PR <i>N</i> | SD <i>N</i> | PD <i>N</i> | NE <i>N</i> | ORR <i>N</i> (%; 95%CI) [#] |
|---------------------|----------------|----------------|----------------|----------------|----------------|---|
| Stomach | 1 | 5 | 1 | 3 | 1 | 6 (54.5%; 24-83%) |
| Ocular adnexa | 0 | 4 | 3 | 0 | 1 | 4 (50%; 16-84%) |
| Lung | 2 | 2 | 0 | 1 | 1 | 4 (67%; 22-96%) |
| Salivary glands | 0 | 0 | 3 | 1 | 0 | 0 (0%; 0-60%)* |
| Liver | 1 | 0 | 3 | 0 | 0 | 1 (25%; 0.6-81%) |
| Skin | 0 | 1 | 1 | 0 | 1 | 1 (33%; 0.8-91%) |
| Subcutaneous tissue | 1 | 0 | 0 | 0 | 1 | 1 (50%; 1.25-99%) |
| Breast | 1 | 0 | 1 | 0 | 0 | 1 (50%; 1.25-99%) |
| Kidney | 0 | 1 | 0 | 0 | 0 | 1 (100%; 2.5-100%)* |
| Bone | 0 | 0 | 1 | 0 | 0 | 0 (0%; 0-97.5%)* |
| Muscle | 0 | 0 | 1 | 0 | 0 | 0 (0%; 0-97.5%)* |

CR, complete remission; PR, partial remission, SD, stable disease; PD, progression of disease; NE not evaluable; ORR, overall response rate.

[#] Percentage and 95%CI refer to the intent-to-treat population.

* One-sided, 97.5% CI.